Cholesterol, blood pressure, and the silent decade for men 35-55

Atherosclerosis, the underlying cause of most heart attacks and strokes, builds slowly over decades. Autopsy studies of young soldiers killed in combat have shown early plaque in the coronary arteries of men in their twenties and thirties. The plaque does not produce symptoms until it is large enough to obstruct blood flow or unstable enough to rupture, which is often in the fifties or sixties. The 35-55 stretch is where most of the silent damage happens.

This is the bad news and the good news. The bad news is that "feeling fine" is not a useful indicator of cardiovascular health in middle age. The first symptom of coronary disease is a heart attack in roughly half of cases. The good news is that the damage is largely preventable. Every major risk factor (blood pressure, LDL, apoB, blood sugar, smoking, excess weight) is modifiable, and the modifications produce measurable results.

The 35-55 window is the period of highest leverage. Risk factor changes made in this stretch produce decades of compound benefit. Risk factor changes made at 65 still help, but the curve is steeper for changes made earlier.

Hypertension is the single largest preventable cause of cardiovascular disease worldwide. It is also the most underdiagnosed and undertreated. Roughly half of American adults with high blood pressure do not have it controlled, and a meaningful fraction do not know they have it.

The current guideline thresholds (from the 2017 ACC/AHA guideline) are normal under 120/80, elevated 120-129/under 80, stage 1 hypertension 130-139/80-89, and stage 2 hypertension 140+/90+. The thresholds dropped meaningfully in 2017 because the underlying trial data, particularly SPRINT, showed that lower blood pressure targets reduced cardiovascular events even in patients who looked healthy by older standards.

Blood pressure should be measured correctly to be meaningful. That means seated, feet flat, back supported, after 5 minutes of rest, with the arm at heart level, on a properly sized cuff. Numbers taken in a hurry at the end of a doctor visit, or at a kiosk in a pharmacy, are unreliable. Home monitoring with a validated device is one of the most underused tools in primary care, and it routinely identifies both white-coat hypertension and masked hypertension that gets missed in clinic.

For most adults with stage 1 or stage 2 hypertension, treatment is straightforward and effective. Lifestyle changes (sodium reduction, weight loss, exercise, alcohol moderation, stress management) can move blood pressure 5-15 mmHg. Medications, when needed, are inexpensive and well-tolerated. The barrier is identification and follow-through, not the existence of effective treatment.

For decades, the standard cholesterol panel has reported total cholesterol, HDL, LDL, and triglycerides. LDL ("bad" cholesterol) is a calculation from the other numbers and is the closest thing to a single risk number on the standard panel.

A more accurate marker is apoB, which counts the actual number of atherogenic particles (LDL, VLDL, and others) in the bloodstream. Each of these particles carries one apoB molecule, regardless of size. Two patients can have the same LDL-C but very different apoB if their LDL particles differ in size and density, and the apoB number predicts events more accurately than LDL-C alone.

The apoB test is inexpensive, increasingly available, and worth asking for at any cardiovascular workup. For non-diabetic adults at moderate risk, an apoB under 90 mg/dL is a reasonable starting goal; lower is better in patients with established disease or strong family history.

The other useful add-on is lipoprotein(a), or Lp(a), which is a genetically determined cholesterol-like particle that adds independently to risk. Roughly 20% of the population has elevated Lp(a) and most do not know it. The number is largely unmodifiable but it raises the bar on how aggressively the modifiable risk factors should be managed. It is worth measuring once in your life, particularly if there is a family history of premature cardiovascular disease.

A frequent and dangerous reflex in middle-aged men is to skip cardiovascular workups because of subjective wellness. Energy is decent, the gym session went fine, no symptoms have shown up. The conclusion is that there is nothing to check.

This reasoning is wrong on the underlying biology. Plaque buildup, hypertension, and elevated LDL produce no symptoms until the disease is advanced. Blood pressure can sit at 150/95 for a decade without the patient noticing anything. apoB can be high enough to drive significant plaque progression in a man who feels great.

The right framing is that cardiovascular workups are a screening tool for silent disease, similar in spirit to colonoscopy or skin checks. The point is to catch what is there before it becomes the kind of thing you can feel. Waiting for symptoms is the failure mode this entire field is trying to avoid.

A useful baseline workup for a 35-55 year old man includes blood pressure (ideally home-monitored), a fasting lipid panel including apoB, a fasting glucose and HbA1c, and a calculation of 10-year cardiovascular risk using a tool like the AHA-ACC ASCVD risk calculator. Patients with abnormal numbers, family history, or moderate-to-high risk should have a longer conversation with a clinician about additional testing (Lp(a), CT calcium score) and treatment.

The lifestyle interventions with the strongest evidence for cardiovascular outcomes are the same ones that show up in nearly every chronic-disease conversation: regular physical activity, body weight in a reasonable range, a Mediterranean-style eating pattern, modest or no alcohol, no smoking, and adequate sleep.

On blood pressure specifically, sodium reduction is the most reliable lever. The American diet averages 3500 mg of sodium per day; trial evidence shows meaningful blood pressure reduction in salt-sensitive patients when intake drops below 2000-2300 mg per day. The DASH eating pattern (vegetables, fruits, whole grains, low-fat dairy, lean protein, low sodium) lowers blood pressure as much as a single antihypertensive medication in trials, particularly in salt-sensitive patients.

On LDL and apoB, soluble fiber, plant sterols, and reducing saturated fat all lower the numbers, though the effects are modest individually and add up when combined. Exercise has a small direct effect on LDL but a larger effect on triglycerides and HDL. Body weight reduction in overweight patients reliably improves the entire panel.

The unfortunate reality is that lifestyle changes alone are often insufficient for patients with significantly elevated apoB, strong family history, or established disease. They reduce risk meaningfully and they are worth doing for everyone, but the evidence for medication on top of lifestyle in higher-risk patients is robust enough that combining the two is usually the right approach.

Statins remain the most studied and most evidence-supported class of cholesterol-lowering medications. In patients at clear elevated risk (established cardiovascular disease, diabetes, very high LDL, or 10-year risk above a threshold), statins reduce major cardiovascular events by roughly 25-35% per 1.0 mmol/L reduction in LDL. The relative benefit is durable across decades of follow-up.

The decision to start a statin is more nuanced for patients in the borderline-risk range. The current guidelines use 10-year risk thresholds, family history, biomarkers, and patient preferences to guide the decision. For a 45-year-old man with moderate risk, normal blood pressure, and modestly elevated LDL, the conversation might land on "lifestyle first, recheck in 6-12 months, statin if numbers do not improve." For a 50-year-old with strong family history and high apoB, the conversation more often lands on "start a statin now."

Side effects of statins are real but smaller than the popular discussion suggests. The most common is muscle aches, which affects perhaps 5-10% of patients and is usually manageable with dose adjustment or switching to a different statin. The widely circulated concerns about statins and cognitive decline have not held up in trials. The diabetes risk is small in absolute terms and is outweighed by cardiovascular benefit in patients with clear indications.

Newer medications including ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran have expanded the options for patients who cannot tolerate statins or need additional LDL lowering. The conversation has gotten more personalized over the last decade, which is a good thing. The decisions are best made jointly with a clinician who knows your numbers and your history, not from internet generalizations.

For a 35-55 year old man who wants to know where to start, the practical action list is short. Get blood pressure measured properly and start home monitoring if it is anywhere close to elevated. Get a lipid panel including apoB, and consider a one-time Lp(a) measurement. Calculate your 10-year cardiovascular risk and have a conversation with a clinician about what the number means.

On lifestyle, prioritize blood pressure (sodium, weight, exercise, alcohol) and LDL/apoB (Mediterranean pattern, soluble fiber, saturated fat moderation) as the two largest levers. Both respond meaningfully within months to consistent changes.

If your numbers do not move enough with lifestyle and your risk is meaningful, do not delay the medication conversation for years. The evidence base for treating elevated risk in middle age is strong, the medications are inexpensive and well-tolerated, and the alternative is taking a chance with the most common cause of death in your demographic.

The cardiovascular system is not the part of the body that asks nicely. It does its work quietly until it does not. The 35-55 window is the part of life where it is easiest to influence, and that is the window worth taking seriously.